Navigation Links
Extended Therapy for Blood Clots

An oral drug given after a standard six-month treatment could help prevent future blood clots in patients, according to new research.//

Venous thromboembolism (VTE) affects approximately 2 million Americans each year. VTE includes deep vein thrombosis (blood clots common in the thigh and back) and pulmonary embolism (blood clots common in the lung). Despite progress in diagnosis and treatment, VTE is still associated with high morbidity and mortality. While previous studies have shown a risk of recurrence after six months, treatment is often stopped after six months because of the risk of bleeding. A new study examines the use of the oral drug ximelagatran or placebo as a treatment after the six-month standard treatment.

The study included 1,233 patients with VTE who had six months of anticoagulant therapy. Half of the patients were then given the drug ximelagatran and the other half was given a placebo for 18 months. Researchers then analyzed how the patients did on the drug compared to those on the placebo.

Researchers report only 12 patients on ximelagatran had a recurrent problem compared with 71 patients on the placebo. They found six patients on the drug died during the 18 months compared with seven patients who died in the placebo group. However, 134 patients on ximelagatran experienced bleeding compared to 111 patients on the placebo. Still, study authors point out that the risk of major hemorrhage was low. Researchers say those patients on ximelagatran had high levels of alanine aminotransferase which is an enzyme present in the liver and heart cells. The levels of this enzyme in patients on the drug were more than three-times the normal level and cause a concern for more research on this treatment, according to study authors.

In conclusion, researchers say the drug ximelagatran is superior to placebo for an extended treatment for VTE. However, they say more research is needed to understand why patients on the tre atment had high levels of a certain enzyme.
'"/>




Related medicine news :

1. Breast Cancer Funding To Be Extended By Another $30 Million: Pharmac
2. Drug Courts In Europe Extended For Three More Years
3. Single Dose Of Extended Release Metformin Found To Be Effective In Type 2 Diabetes
4. Tenure of Mental Health CommissionExtended
5. Pharmaceutical Benefits Scheme Extended for 2 Novel Breast Cancer Drugs
6. Babies with Cleft Conditions, Pierre Robin Sequence May Need Extended Treatment for Poor Feeding Skills
7. Survival of Mice With Human Breast Cancer Extended by Monoclonal Antibodies
8. Cancer Doctors Okays Controversial Prostate Therapy
9. Consensus on "Combination Therapy" for Breast Cancer
10. Gene Therapy shows promise in treating Hemophilia
11. "Make AIDS Therapy affordable" - Physicians demand
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/25/2017)... ... September 25, 2017 , ... “Renew Refresh Restore Reward”: is a story ... is the creation of published author, Deborah Freeman, cofounded the Free Spirit Bible Church ... returned to our cars, my sister-in-law invited us to come over before the baby ...
(Date:9/25/2017)... ... September 25, 2017 , ... “The Majestic Unicorn”: a ... flood. “The Majestic Unicorn” is the creation of published author, Dayna Chantel, an artist ... from far and wide to march aboard the cypress ark-vessel. Male and female, no ...
(Date:9/25/2017)... New York, NY and Los Angeles, CA (PRWEB) , ... September ... ... City, has announced the opening of a full-time office in downtown Los Angeles, to ... Texas, Arizona, Nevada and the surrounding areas. , “We are seeing an ever-increasing amount ...
(Date:9/25/2017)... ... September 25, 2017 , ... ... September 28, 2017 to deliver a powerful message of teamwork, unity and collaboration ... Feature film writer/director Robert Adetuyi (Beat the World, Stomp the Yard) and Grammy-nominated ...
(Date:9/24/2017)... ... September 25, 2017 , ... The Venetian on Grace Bay in ... 1st. And, throughout the month of October, the resort will be offering 40% ... and Maria have passed and damage to the Venetian was very minimal and mostly ...
Breaking Medicine News(10 mins):
(Date:9/18/2017)... PROVIDENCE, R.I. , Sept. 18, 2017 ... in the fields of bioinformatics and immune ... to develop a protective avian influenza A (H7N9) vaccine. ... is distantly related to seasonal influenza and ... approaches, which rely on prior exposure to be ...
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., the ... (VLMS), is pleased to announce the appointment of ... of its Board of Directors and Chairman of ... enables life science companies to manage their entire ... of paper in this process. Furthermore, ValGenesis VLMS ...
(Date:9/7/2017)... 2017  Eli Lilly and Company (NYSE: ... operations to more efficiently focus resources on developing ... Global workforce reductions, including those from a U.S. ... approximately 3,500 positions. With the ... of approximately $500 million that will begin to ...
Breaking Medicine Technology: